Stocks · News reference
PDS Biotechnology Corporation has expanded its Board of Directors with the appointment of three new members with extensive pharmaceutical industry experience.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
PDS Biotechnology Corporation announced that NantWorks has exercised warrants to purchase over 17.6 million shares of common stock, generating approximately $3.9 million in gross proceeds.
Filed: 2026-11-10 AccNo: 0001140361-26-042898 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
B. Riley Securities has maintained its 'Buy' rating on PDS Biotechnology while increasing the price target from $3 to $4.
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.